Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Gamma-aminobutyric acid (GABA) is the most important inhibitory transmitter in the central nervous system and inhibits the stimulatory effects of beta-adrenergic neurotransmitters epinephrine and norepinephrine. In recent years, there is increasing evidence that GABA metabolism-related genes, the 4-aminobutyrate aminotransferase (ABAT) gene, is closely linked to many diseases of the nervous system and play an important role in other diseases such as digestive, neoplastic, and hematological diseases.
The ABAT gene is located at 16p13.2, is 56 kb in length, and encodes a protein of GABAT. ABAT gene has three co-dominant alleles, ABAT1, ABAT2, and ABAT3, respectively. ABAT gene expression in different tissues is inconsistent, and the corresponding ABAT mRNA expression levels from high to low are liver, pancreas, brain, kidney, heart, and placenta, and lung is difficult to detect. The activities of GABAT in different tissues are also different. The activities of brain and spinal cord are the highest, followed by peripheral tissues. From high to low are liver, kidney, lung, heart, stomach and peripheral platelets, respectively. ABAT gene expression levels and enzyme activity Inconsistency suggests that there may be differences in the regulation of enzyme activity in different tissues.
The function of the ABAT gene is mainly to encode GABAT and participate in the catabolism of GABA. In addition, ABAT gene also participates in the salvage synthesis pathway of mitochondrial nucleotides and promotes the conversion of deoxyribonucleoside diphosphates into deoxyribonucleoside triphosphates. Moreover, it maintains mitochondrial membrane function and mitochondrial respiratory chain complex activity.
The Progress of ABAT Gene in Neuropsychiatric Diseases
Emotional disorders
Wegerer et al. initiated a prospective high-risk study (Munich Vulnerability Study) with 83 patients with list/bipolar disorder in 12 families to discover the molecular biology of affective disorders, wanted to find susceptibility indicators in the molecular biology of affective disorders. Of these, 69 patients consented to electroencephalography, genotyping, psychiatric investigations, and somatosensory evoked potential acquisition procedures, followed by screening for genes encoding important substances in the 5-hydroxytryptamine, GABAergic, and substance P systems. Among the 25 candidate genes related to affective disorders, 176 SNPs were found in these candidate genes. Further analysis revealed that only 4 SNP sites in the 3′-UTR region of ABAT gene, rs2270288, rs3743798, rs3743801, and rs7205816, are strongest associated with disease, suggesting that the single nucleotide variation of the ABAT gene can be used as a susceptibility indicator of affective disorders.
Autosomal recessive mitochondrial depletion syndrome
Besse et al. found that the ABAT gene is involved in the salvage synthesis pathway of mitochondrial nucleotides. SUCLG1, SUCLG2, SUCLA2, and NDPK function as interactors of the GABAT protein regulate mitochondrial nucleotide metabolism. ABAT gene mutations can cause autosomal recessive mitochondrial depletion syndrome. In this study, homozygous missense mutations in the ABAT gene (613C>T) were detected in exon in one of the patients, but no mutation was found in 61,486 normal controls. In another patient, Sanger sequencing revealed homozygous mutations in the ABAT gene and proved to be inherited implicitly—their parents were heterozygous (carriers). Missense mutations in the ABAT gene can cause decreased mitochondrial DNA levels in myofibroblasts, reduced mitochondrial respiratory chain complex activity, and decreased mitochondrial membrane function in these patients, causing neurometabolic disorders including autosomal recessive mitochondrial depletion syndrome. The authors further knocked out the ABAT gene in human normal embryonic fibroblast cell lines and found that GABAT deficiency, elevated GABA content, decreased mitochondrial copy number, and decreased mitochondrial membrane function can be caused. The above situation was also seen in the aminoquenoic acid with the inhibitor of GABAT, confirming the conclusion of this study.
Figure 1. ABAT in mitochondrial nucleoside metabolism. (Besse, et al. 2015).
The Progress of ABAT Gene in Tumor Diseases
The mutation rate of the ABAT gene is very low, and most studies have focused on GABA and its receptors. GABA binds to its A or B receptor and participates in tumor proliferation and apoptosis through various signaling pathways, such as gastric cancer, breast cancer, and pancreatic cancer. Wang et al. found that in the blood system, peripheral blood mononuclear cells express GABAA receptors on the surface, and mononuclear cells in the bone marrow highly express GABAA receptors and participate in the development of acute lymphoblastic leukemia. Mutation or abnormal methylation of the ABAT gene increases GABA content and is one of the possible pathogenic mechanisms. Budczies et al. confirmed that β-alanine was elevated and GABAT expression was decreased in ER-breast cancer patients. A β-alanine level was negatively correlated with GABAT content. The low expression of ABAT gene was closely related to the poor prognosis of breast cancer. Studies confirmed a positive correlation between GABAT levels and ABAT gene mRNA levels. Jansen et al. studied the association between the low expression of ABAT gene and the poor prognosis of breast cancer. The results of the study showed that high gene scores and low expression of ABAT and STC2 were associated with progression-free survival (PFS), indicating that these three indicators could serve as prognostic indicators for breast cancer.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.